Redhill Biopharma Ltd. Form 6-K Summary
Business Context and Reporting Period
This Form 6-K, filed on November 13, 2018, by Redhill Biopharma Ltd., a foreign private issuer based in Tel Aviv, Israel, incorporates by reference the Company's press release and unaudited financial information for the third quarter ended September 30, 2018.
Key Financial Metrics
The filing text provided does not contain specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. These metrics are contained within the attached exhibits (Exhibit 1 and Exhibit 2) which are referenced but not included in the source text.
Material Changes
The filing text does not provide specific details regarding material changes versus the prior comparable period. The document serves as a cover sheet to incorporate the detailed financial results and business highlights found in the attached exhibits.
Guidance, Outlook, and Risks
Management commentary, guidance, outlook, risks, contingencies, and unusual items are not detailed in the provided text. The filing indicates that this information is available in the incorporated press release and condensed consolidated interim financial statements.
Investor Verification Checklist
- Review Exhibit 1 for the full text of the Third Quarter 2018 financial results and business highlights.
- Examine Exhibit 2 for the condensed consolidated interim unaudited financial statements as of September 30, 2018.
- Verify the specific figures for net loss, cash burn rate, and remaining cash runway in the attached exhibits.
- Confirm any updates on clinical trial progress or regulatory milestones mentioned in the press release.